Clinical and Mechanistic Insights Into Novel Agents in Development for Osteoporosis
Release date: June 2009
Expiration date: June 30, 2010
Estimated time to complete activity: 45 minutes
This educational initiative is co-sponsored by Curatio CME Institute and the National Osteoporosis Foundation. Current Medical Evidence™ is a registered trademark of Curatio CME Institute. Content expertise has been provided by the National Osteoporosis Foundation.
Support for this activity has been provided through an educational donation from
Activity Overview
Osteoporosis develops when bone resorption occurs at a faster rate than bone replacement, causing an imbalance in the bone remodeling process. Current research into the development of new osteoporosis-treatment drugs focuses on agents that target molecular pathways and the specific enzymes involved in the bone remodeling pathway, such as the receptor activator of nuclear factor-κB (RANK) and Wnt pathways and cathepsin K. This activity discusses how an improved understanding of the pathophysiology of postmenopausal osteoporosis has contributed to the development of potential new therapies.
Target Audience
This activity has been designed to meet the educational needs of physicians and other health care professionals in endocrinology, rheumatology, obstetrics/gynecology, and primary care who manage patients who have or are at risk for osteoporosis.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the normal bone remodeling process and how osteoporosis results from an imbalance in the bone remodeling process
- Identify the molecular pathways that are the current targets of investigation into new treatments for osteoporosis
- Describe new agents in development, their mechanisms of action, and clinical data related to their use in osteoporosis
Editors
Felicia Cosman, MD
David W. Dempster, PhD
Faculty
Felicia Cosman, MD—Chair
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
New York, New York
Medical Director, Clinical Research Center
Helen Hayes Hospital
West Haverstraw, New York
David W. Dempster, PhD
Professor of Clinical Pathology
Columbia University College of Physicians and Surgeons
New York, New York
Director, Regional Bone Center
New York State Department of Health
Helen Hayes Hospital
West Haverstraw, New York
Margery L. S. Gass, MD
Professor of Clinical Obstetrics and Gynecology
Director, University Hospital Menopause and Osteoporosis Center
University of Cincinnati College of Medicine
Cincinnati, Ohio
Jeffrey P. Levine, MD, MPH
Associate Professor
Departments of Family Medicine and Obstetrics, Gynecology & Reproductive Sciences
Director of Women's Health Programs, Department of Family Medicine
Master Educators Guild
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey
Michael J. Maricic, MD
Clinical Associate Professor of Medicine
University of Arizona School of Medicine
Co-Director, Clinical Research
Catalina Pointe Rheumatology
Tucson, Arizona
Susan Randall, RN, MSN, FNP-BC
Senior Director, Education
National Osteoporosis Foundation
Washington, District of Columbia
Accreditation Statement
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period June 2009 to June 30, 2010, participants must (1) read the learning objectives and disclosure statements, (2) study the entire educational activity, (3) complete the presurvey and postsurvey, and (4) complete the activity evaluation form.
The posttest can be accessed at the end of the activity. Please e-mail any questions to cmeinfo@curatiocme.com.
Media
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Disclosure
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Felicia Cosman, MD, has disclosed the following relevant financial relationships:
| Advisory Board | Amgen, Eli Lilly, Merck, Novartis |
| Consultant | Amgen, Merck, Novartis, Pfizer |
| Speaker | Eli Lilly, Merck, Novartis |
Dr. Cosman discusses the unlabeled or investigational use of a commercial product.
David W. Dempster, PhD, has disclosed the following relevant financial relationships:
| Consultant | Amgen, Eli Lilly, Merck |
| Speaker | Eli Lilly, Procter & Gamble, Sanofi Aventis |
Margery L. S. Gass, MD, has disclosed the following relevant financial relationships:
| Consultant | Eli Lilly, Palatin Technologies, Procter & Gamble, Roche, Sciele, Upsher-Smith Laboratories, Wyeth |
| Research | Boehringer-Ingelheim, Organon, Procter & Gamble, Wyeth |
Jeffrey P. Levine, MD, MPH, has disclosed the following relevant financial relationships:
| Consultant | Novartis, Wyeth |
Dr. Levine discusses the unlabeled or investigational use of a commercial product.
Michael J. Maricic, MD, has disclosed the following relevant financial relationships:
| Advisor, Grants, Research, Speaker | Amgen, Eli Lilly, Merck, Novartis, Procter & Gamble, Roche |
National Osteoporosis Foundation
Susan Randall, RN, MSN, FNP-BC, Senior Director, Education, has disclosed no relevant financial relationships.
Curatio CME Institute
Shari Dermer, PhD, Medical Director, has disclosed no relevant financial relationships.
Thomas Finnegan, PhD, Medical Writer, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Derek Warnick, CME Director, has disclosed no relevant financial relationships.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, the National Osteoporosis Foundation, and Amgen do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, the National Osteoporosis Foundation, or Amgen. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This educational initiative is co-sponsored by Curatio CME Institute and the National Osteoporosis Foundation. OsteoporosisTX.com is owned and operated by Curatio CME Institute with content expertise provided by the National Osteoporosis Foundation.
| Generic Name | Trade Name | Approved Use (if any) | Unapproved/ Investigational Use |
| Arzoxifene | N/A | N/A | Treatment of low bone mass in postmenopausal women |
| Bazedoxifene | N/A | N/A | Prevention and treatment of postmenopausal osteoporosis |
| Denosumab | N/A | N/A | Treatment of low bone mass or osteoporosis in postmenopausal women |
| Lasofoxifene | N/A | N/A | Treatment of low bone mass or osteoporosis in postmenopausal women |
| Odanacatib | N/A | N/A | Treatment of bone mass or osteoporosis in postmenopausal women |
| ZT-031 | Ostabolin-C® | N/A | Treatment of low bone mass or osteoporosis in postmenopausal women |
| Sclerostin antibody | N/A | N/A | Use in healthy postmenopausal women |
| Strontium ranelate | Protelos® | Indicated for the treatment of osteoporosis in postmenopausal women* | Treatment of postmenopausal osteoporosis |
| Tibolone | Livial® | Indicated for the treatment of estrogen deficiency symptoms in postmenopausal women, more than 1 year after menopause. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.* | Treatment of postmenopausal osteoporosis |
* Not approved for use in the United States
Hardware/Software Requirements
- Javascript-enabled browser
- Active Internet connection
- Adobe Acrobat Reader
- Adobe Flash Player plugin v.8.0+
Contact Information
OsteoporosisTX.com
100 Campbell Boulevard
Suite 103
Exton, PA 19341
OsteoporosisTX@curatiocme.com
Policy on Privacy and Confidentiality
Curatio CME Institute makes every effort to protect the privacy of OsteoporosisTX.com users; user information is used only to maintain records as required by the American Medical Association (AMA) and the ACCME.
Curatio CME Institute does not require individuals to register to use OsteoporosisTX.com; registration is only required for physicians, health care professionals, and other users to participate in and receive CME/CE credit for accredited educational programs hosted on OsteoporosisTX.com.
Curatio CME Institute is required by the AMA and the ACCME (and occasionally by other accrediting organizations) to collect user information that will allow Curatio CME Institute to issue a CME/CE certificate. Curatio CME Institute is required to keep this information on file for up to 6 years. The information is stored in a secure database and used only to verify individual participation in a CME/CE activity and to reissue a certificate if a user's original certificate is lost or misplaced.
Information gathered through OsteoporosisTX.com will not be released to any other company or organization for any purpose; this information remains confidential. At the end of the mandatory 6-year period, these records will be destroyed.
Curatio CME Institute uses Web site tracking software to determine how OsteoporosisTX.com is used. This information helps Curatio CME Institute determine the best strategies for improving OsteoporosisTX.com and better meeting the needs of its users. This software does not identify individual users.
OsteoporosisTX.com does not employ cookies or any other software that violates a user's privacy.
If you have any questions about OsteoporosisTX.com or any Curatio CME Institute policies, you may contact us at OsteoporosisTX@curatiocme.com.
Thank you for using OsteoporosisTX.com
